Item 7.01 Regulation FD Disclosure.

On October 8, 2021, Repare Therapeutics Inc. (the "Company"), issued a press release announcing initial Phase 1 monotherapy clinical data from its ongoing Phase 1/2 TRESR clinical trial of RP-3500. As described in the press release, the Company will present the initial Phase 1 monotherapy clinical data from the ongoing Phase 1/2 TRESR clinical trial at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics on October 8, 2021. In addition, at 5:00 p.m. Eastern Time on October 8, 2021, following the AACR-NCI-EORTC oral presentation, the Company will host a virtual investor webcast where members of the Company's management team will present further details regarding the Phase 1/2 TRESR clinical trial. The virtual event and related materials can be accessed via the News and Events section of the Company's website and will be available for 90 days following the event. A copy of the press release is furnished as Exhibit 99.1 to this Current Report and incorporated herein by reference.

The information under this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibit.




(d) Exhibits



Exhibit
No.                      Description

99.1        Press release dated October 8, 2021.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses